Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Wave Life Sciences (WVE) will participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on September 10, 2026 at 9:45 a.m. ET.
Rhea-AI Summary
Wave Life Sciences (WVE) will participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on September 10, 2026 at 9:45 a.m. ET.
A live webcast and a time-limited replay will be available via the company’s Investor Events webpage.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | Redomiciliation completion | Neutral | -0.5% | Parent company changed from a Singapore entity to a Delaware corporation. |
| Aug 05 | Redomiciliation timing | Neutral | +1.5% | Company confirmed expected completion timing and required Singapore and SEC filings. |
| Aug 04 | Conference presentations | Neutral | +4.5% | Management announced participation in two August investor conference fireside chats. |
| Jul 30 | 2Q26 earnings report | Negative | -0.9% | Revenue declined while net loss and operating expenses increased year over year. |
| Jul 23 | Earnings scheduling notice | Neutral | +0.7% | Company scheduled its second-quarter results webcast and business update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent reactions were mixed, including a 4.53% gain after a conference announcement and a 0.86% decline after quarterly results.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET.
A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
